TREVI THERAPEUTICS INC (TRVI)
US89532M1018 - Common Stock
TREVI THERAPEUTICS INC
NASDAQ:TRVI (1/6/2025, 8:05:06 PM)
After market: 4.3 -0.02 (-0.46%)4.32
-0.27 (-5.88%)
Company Profile
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. The company is headquartered in New Haven, Connecticut and currently employs 25 full-time employees. The company went IPO on 2019-05-07. The firm is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. The company is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. The company has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Company Info
TREVI THERAPEUTICS INC
195 Church St Fl 14
New Haven CONNECTICUT 06510
P: 12033042499
CEO: Jennifer Good
Employees: 26
Website: https://www.trevitherapeutics.com/
TRVI News
15 days ago - Market News VideoInvestors Snatch TRVI Even Lower Than Its Secondary Stock Offering22 days ago - Trevi Therapeutics, Inc.Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy, Haduvio™ (oral...
26 days ago - Yahoo FinanceWhy Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?On Thursday, Trevi Therapeutics, Inc. (NASDAQ:TRVI) announced the outcome from the planned sample size re-estimation (SSRE) for the ongoing Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) patients with chronic cough, which requires no change to the current sample size for the trial (N=160). The CORAL trial is a double-blind, randomized, placebo-controlled, parallel-arm trial evaluating three doses of Haduvio (27mg, 54mg, and 108mg twice daily) compared to placebo in IPF patients with
26 days ago - Trevi Therapeutics, Inc.Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...
a month ago - Trevi Therapeutics, Inc.Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...
2 months ago - Trevi Therapeutics, Inc.Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...
TRVI Twits
Here you can normally see the latest stock twits on TRVI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
